Latest Headlines

1. PCR Plates Designed To Improve Consistency Of Results 4/24/2025

   Achieving reliable PCR and qPCR results is not just about the reagents—consumables play a crucial role too. 4titude PCR plates from Azenta Life Sciences are optimized to meet the varied and often overlooked needs of modern PCR workflows.

2. Bruker To Launch Beacon Discovery At AACR 2025, Expanding Access To Live Single-Cell Functional Analysis 4/24/2025

   Bruker Corporation today announced the launch of the Beacon Discovery Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis.

3. Augurex Announces UKCA Authorization For SPINEstat, Expanding Access To A First-In-Class Diagnostic Blood Test For Axial Spondyloarthritis To Great Britain 4/23/2025

   Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that SPINEstat has received UK Conformity Assessed (UKCA) marking by the Medicines and Healthcare products Regulatory Agency (MHRA), authorizing the blood test for clinical use and listing it as an in vitro diagnostic (IVD) in Great Britain.

4. Beckman Coulter Life Sciences Transforms Purification With The Launch Of The OptiMATE Gradient Maker 4/23/2025

   Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of the OptiMATE Gradient Maker, a groundbreaking instrument designed to automate the process of density gradient ultracentrifugation (DGUC).

5. Labcorp Launches Molecular Residual Disease And Liquid Biopsy Solutions 4/23/2025

   Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.

6. Baebies Receives FDA Breakthrough Device Designation For First Point-Of-Care Heparin Monitoring Test 4/23/2025

   Baebies has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER® platform —the first point-of-care heparin monitoring assay.

7. Gene Solutions And Element Biosciences Enter Strategic Collaboration To Advance Next-Generation Sequencing (NGS) Technology Globally 4/22/2025

   Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration.

8. Advanced Biological Laboratories (ABL) S.A Inks Licensing Agreement With The Institut Pasteur For HPV RNA-Seq Technology 4/22/2025

   Advanced Biological Laboratories (ABL), a diagnostics company, headquartered in Luxembourg, is pleased to announce a licensing agreement with the renowned Institut Pasteur for the integration of the innovative HPV RNA-Seq technology into its diagnostic solutions.

9. Ginkgo Automation Partners With Aura Genetics To Accelerate Direct-To-Consumer Testing And Innovation 4/22/2025

   Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market.

10. Veravas Launches VeraBIND™ Tau - First Blood Test To Detect Alzheimer's-Related Tau Pathology 4/22/2025

    Veravas, a leader in clinical diagnostics, today announced the general commercial availability of VeraBIND™ Tau, the first blood-based test designed to aid in the detection of Alzheimer's disease (AD) and other tau-related neurodegenerative disorders (tauopathies).